Pre-order Enquiry
Request Free Sample
Global Alpha 1 Antitrypsin Deficiency Treatment Market Research Report 2022
SKU ID : QYR-21064748 | Publishing Date : 10-Jun-2022
Request Sample
Request Customization
Check DiscountsDetailed TOC of Global Alpha 1 Antitrypsin Deficiency Treatment Market Research Report 2022
1 Report Overview1.1 Study Scope
1.2 Market Analysis by Indication
1.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Indication: 2017 VS 2021 VS 2028
1.2.2 Augmentation Therapy
1.2.3 Cystic Fibrosis(CF)
1.2.4 Non-CF Bronchiectasis(NCFB)
1.2.5 Diabetes
1.2.6 Other
1.3 Market by End Users
1.3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users: 2017 VS 2021 VS 2028
1.3.2 COPD
1.3.3 Cystic Fibrosis(CF)
1.3.4 Non-CF Bronchiectasis(NCFB)
1.3.5 Diabetes
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Perspective (2017-2028)
2.2 Alpha 1 Antitrypsin Deficiency Treatment Growth Trends by Region
2.2.1 Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Region (2017-2022)
2.2.3 Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2023-2028)
2.3 Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics
2.3.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends
2.3.2 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
2.3.3 Alpha 1 Antitrypsin Deficiency Treatment Market Challenges
2.3.4 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue
3.1.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue (2017-2022)
3.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Alpha 1 Antitrypsin Deficiency Treatment Revenue
3.4 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio
3.4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Alpha 1 Antitrypsin Deficiency Treatment Revenue in 2021
3.5 Alpha 1 Antitrypsin Deficiency Treatment Key Players Head office and Area Served
3.6 Key Players Alpha 1 Antitrypsin Deficiency Treatment Product Solution and Service
3.7 Date of Enter into Alpha 1 Antitrypsin Deficiency Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by Indication
4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Indication (2017-2022)
4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (2023-2028)
5 Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by End Users
5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by End Users (2017-2022)
5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (2023-2028)
6 North America
6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)
6.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)
6.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)
7.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)
7.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)
8.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)
8.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)
9.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)
9.3 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)
10.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)
10.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.1.4 Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.1.5 Pfizer Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Detail
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.2.4 GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.2.5 GlaxoSmithKline Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.3.4 AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.3.5 AstraZeneca Recent Development
11.4 Boehringer Ingelheim
11.4.1 Boehringer Ingelheim Company Detail
11.4.2 Boehringer Ingelheim Business Overview
11.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.4.4 Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.4.5 Boehringer Ingelheim Recent Development
11.5 Teva Pharmaceutical Industries
11.5.1 Teva Pharmaceutical Industries Company Detail
11.5.2 Teva Pharmaceutical Industries Business Overview
11.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.5.4 Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.5.5 Teva Pharmaceutical Industries Recent Development
11.6 Takeda
11.6.1 Takeda Company Detail
11.6.2 Takeda Business Overview
11.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.6.4 Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.6.5 Takeda Recent Development
11.7 Baxter
11.7.1 Baxter Company Detail
11.7.2 Baxter Business Overview
11.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.7.4 Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.7.5 Baxter Recent Development
11.8 Grifols
11.8.1 Grifols Company Detail
11.8.2 Grifols Business Overview
11.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.8.4 Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.8.5 Grifols Recent Development
11.9 CSL Behring
11.9.1 CSL Behring Company Detail
11.9.2 CSL Behring Business Overview
11.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.9.4 CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.9.5 CSL Behring Recent Development
11.10 Kamada Ltd
11.10.1 Kamada Ltd Company Detail
11.10.2 Kamada Ltd Business Overview
11.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.10.4 Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.10.5 Kamada Ltd Recent Development
11.11 Chiesi Pharmaceuticals
11.11.1 Chiesi Pharmaceuticals Company Detail
11.11.2 Chiesi Pharmaceuticals Business Overview
11.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.11.4 Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.11.5 Chiesi Pharmaceuticals Recent Development
11.12 Kedrion Group
11.12.1 Kedrion Group Company Detail
11.12.2 Kedrion Group Business Overview
11.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.12.4 Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.12.5 Kedrion Group Recent Development
11.13 Vertex Pharmaceuticals
11.13.1 Vertex Pharmaceuticals Company Detail
11.13.2 Vertex Pharmaceuticals Business Overview
11.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.13.4 Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.13.5 Vertex Pharmaceuticals Recent Development
11.14 ProMetic Life Sciences
11.14.1 ProMetic Life Sciences Company Detail
11.14.2 ProMetic Life Sciences Business Overview
11.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.14.4 ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.14.5 ProMetic Life Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Figures, Tables and Charts Available in Global Alpha 1 Antitrypsin Deficiency Treatment Market Research Report 2022
List of TablesTable 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Indication (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Augmentation Therapy
Table 3. Key Players of Cystic Fibrosis(CF)
Table 4. Key Players of Non-CF Bronchiectasis(NCFB)
Table 5. Key Players of Diabetes
Table 6. Key Players of Other
Table 7. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth by End Users (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2017-2022)
Table 11. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2023-2028)
Table 13. Alpha 1 Antitrypsin Deficiency Treatment Market Trends
Table 14. Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
Table 15. Alpha 1 Antitrypsin Deficiency Treatment Market Challenges
Table 16. Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
Table 17. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Players (2017-2022)
Table 19. Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha 1 Antitrypsin Deficiency Treatment as of 2021)
Table 20. Ranking of Global Top Alpha 1 Antitrypsin Deficiency Treatment Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Alpha 1 Antitrypsin Deficiency Treatment Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Alpha 1 Antitrypsin Deficiency Treatment Product Solution and Service
Table 24. Date of Enter into Alpha 1 Antitrypsin Deficiency Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022) & (US$ Million)
Table 27. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2017-2022)
Table 28. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (2023-2028) & (US$ Million)
Table 29. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2023-2028)
Table 30. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022) & (US$ Million)
Table 31. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2017-2022)
Table 32. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (2023-2028) & (US$ Million)
Table 33. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2023-2028)
Table 34. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 35. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 36. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 37. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 38. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 39. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2023-2028) & (US$ Million)
Table 40. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 41. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 42. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 43. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 44. Pfizer Company Detail
Table 45. Pfizer Business Overview
Table 46. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product
Table 47. Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 48. Pfizer Recent Development
Table 49. GlaxoSmithKline Company Detail
Table 50. GlaxoSmithKline Business Overview
Table 51. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product
Table 52. GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 53. GlaxoSmithKline Recent Development
Table 54. AstraZeneca Company Detail
Table 55. AstraZeneca Business Overview
Table 56. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product
Table 57. AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 58. AstraZeneca Recent Development
Table 59. Boehringer Ingelheim Company Detail
Table 60. Boehringer Ingelheim Business Overview
Table 61. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product
Table 62. Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 63. Boehringer Ingelheim Recent Development
Table 64. Teva Pharmaceutical Industries Company Detail
Table 65. Teva Pharmaceutical Industries Business Overview
Table 66. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product
Table 67. Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 68. Teva Pharmaceutical Industries Recent Development
Table 69. Takeda Company Detail
Table 70. Takeda Business Overview
Table 71. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product
Table 72. Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 73. Takeda Recent Development
Table 74. Baxter Company Detail
Table 75. Baxter Business Overview
Table 76. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product
Table 77. Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 78. Baxter Recent Development
Table 79. Grifols Company Detail
Table 80. Grifols Business Overview
Table 81. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product
Table 82. Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 83. Grifols Recent Development
Table 84. CSL Behring Company Detail
Table 85. CSL Behring Business Overview
Table 86. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product
Table 87. CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 88. CSL Behring Recent Development
Table 89. Kamada Ltd Company Detail
Table 90. Kamada Ltd Business Overview
Table 91. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product
Table 92. Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 93. Kamada Ltd Recent Development
Table 94. Chiesi Pharmaceuticals Company Detail
Table 95. Chiesi Pharmaceuticals Business Overview
Table 96. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency TreatmentProduct
Table 97. Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 98. Chiesi Pharmaceuticals Recent Development
Table 99. Kedrion Group Company Detail
Table 100. Kedrion Group Business Overview
Table 101. Kedrion Group Alpha 1 Antitrypsin Deficiency TreatmentProduct
Table 102. Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 103. Kedrion Group Recent Development
Table 104. Vertex Pharmaceuticals Company Detail
Table 105. Vertex Pharmaceuticals Business Overview
Table 106. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency TreatmentProduct
Table 107. Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 108. Vertex Pharmaceuticals Recent Development
Table 109. ProMetic Life Sciences Company Detail
Table 110. ProMetic Life Sciences Business Overview
Table 111. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency TreatmentProduct
Table 112. ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 113. ProMetic Life Sciences Recent Development
Table 114. Research Programs/Design for This Report
Table 115. Key Data Information from Secondary Sources
Table 116. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication: 2021 VS 2028
Figure 2. Augmentation Therapy Features
Figure 3. Cystic Fibrosis(CF) Features
Figure 4. Non-CF Bronchiectasis(NCFB) Features
Figure 5. Diabetes Features
Figure 6. Other Features
Figure 7. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users in 2021 & 2028
Figure 8. COPD Case Studies
Figure 9. Cystic Fibrosis(CF) Case Studies
Figure 10. Non-CF Bronchiectasis(NCFB) Case Studies
Figure 11. Diabetes Case Studies
Figure 12. Alpha 1 Antitrypsin Deficiency Treatment Report Years Considered
Figure 13. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 14. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 15. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region: 2021 VS 2028
Figure 16. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Players in 2021
Figure 17. Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha 1 Antitrypsin Deficiency Treatment as of 2021)
Figure 18. The Top 10 and 5 Players Market Share by Alpha 1 Antitrypsin Deficiency Treatment Revenue in 2021
Figure 19. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2017-2028)
Figure 21. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2017-2028)
Figure 25. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. France Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. U.K. Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Nordic Countries Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2017-2028)
Figure 33. China Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. India Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2017-2028)
Figure 41. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2017-2028)
Figure 45. Turkey Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Pfizer Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 48. GlaxoSmithKline Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 49. AstraZeneca Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 50. Boehringer Ingelheim Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 51. Teva Pharmaceutical Industries Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 52. Takeda Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 53. Baxter Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 54. Grifols Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 55. CSL Behring Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 56. Kamada Ltd Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 57. Chiesi Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 58. Kedrion Group Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 59. Vertex Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 60. ProMetic Life Sciences Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Keyplayers in Global Alpha 1 Antitrypsin Deficiency Treatment Market Research Report 2022
PfizerGlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical Industries
Takeda
Baxter
Grifols
CSL Behring
Kamada Ltd
Chiesi Pharmaceuticals
Kedrion Group
Vertex Pharmaceuticals
ProMetic Life Sciences
